More treatment opportunities for people with terminal blood disease

On April 20, the Central Institute of Hematology and Blood Transfusion in collaboration with Roche Vietnam organized a memorandum of understanding and started a cooperative activity to improve treatment capacity and care for blood clotting disorders. and non-Hodgkin lymphoma.
This cooperation agreement aims to support the professional capacity building of health workers in the treatment of a number of hematological diseases, strengthen connections, and cooperate with internal and external Hematology organizations and experts. implementing activities aimed at the interests of patients and the community.

The content of strategic cooperation between the Central Institute of Hematology – Blood Transfusion and Roche Vietnam includes the following main activities: Organize specialized training programs and conferences to improve the capacity and experience of health workers in the care and treatment of hematological diseases; Support and connect the Central Institute of Hematology and Blood Transfusion to approach and participate in cooperation activities with agencies and organizations in Vietnam as well as internationally with the aim of learning and sharing treatment experiences from domestic and foreign experts and specialized centers; Organize activities aimed at patients and the community to propagate and raise awareness about diagnosis and treatment, focusing on hemophilia and non-Hodgkin lymphoma. The Central Institute of Hematology and Blood Transfusion in collaboration with Roche Vietnam organized a memorandum of understanding TS. BS. Bach Quoc Khanh, Director of the Central Institute of Hematology – Blood Transfusion, said: “We always support all the cooperation and support of prestigious organizations in the world for the development of Vietnamese health. , all for the goal of bringing better quality of treatment for patients who unfortunately suffer from blood clotting disorders and malignant blood diseases ”. Mr. Girish Mulye, General Director of Roche Pharma Vietnam emphasized: “Combining Roche’s global strengths and innovative solutions with expertise with the dedication and expertise from the medical team, we wishes to give more opportunities to those unlucky people suffering from this incurable disease. This is also part of the company’s long-term commitment to public health in reducing mortality caused by this group of diseases ”. Hemophila (also known as hemophilia) is an inherited bleeding disease caused by decreased or abnormal function of clotting factor VIII / IX. It is estimated that in Vietnam, there are more than 6,200 people with hemophilia, of which nearly 40% of the patients have not been diagnosed and treated. Non-Hodgkin’s lymphoma is another malignancy that tends to increase rapidly among the elderly in Vietnam, especially in men. In 2018, Vietnam had more than 3,500 new cases and more than 2,100 deaths, ranking 14th in terms of incidence rates among cancers. Like other hematological diseases, Hemophila and non-Hodgkin lymphoma cannot be completely cured, but if detected early and responded well to treatment, patients can still maintain their health and live almost life. normal. The Memorandum of Understanding between the Central Institute of Hematology – Blood Transfusion and Roche Vietnam is expected to be implemented within a year and will be in operation from April 2021. Through domestic and foreign cooperation, this strategic cooperation is expected to bring about many positive changes, helping to strengthen the capacity for hematological care and treatment.